Results 81 to 90 of about 63,989 (248)

The Cancer Immunotherapy Thromboembolism Assessment: A Novel Score for Predicting Thromboembolic Events in Melanoma Patients Treated With Immune Checkpoint Inhibition

International Journal of Cancer, EarlyView.
Although immune checkpoint inhibitors (ICI) have transformed metastatic melanoma treatment, thromboembolic events (TEEs) remain a serious complication. Moreover, existing risk assessment models were developed prior to ICI use and lack clinical validation.
Tim Zell, Julian Kött, Noah Zimmermann, Greta Ancker, Alexander T. Bauer, Daniel J. Smit, Glenn Geidel, Julian C. Gerwers, Thomas Renné, Sebastian A. Wohlfeil, Jochen Utikal, Stefan W. Schneider, Christoffer Gebhardt   +12 more
wiley   +1 more source

Evaluation of Rivaroxaban Exposure via Anti-Xa Levels During VTE Prophylaxis in Hospitalized Patients

Clinical and Applied Thrombosis/Hemostasis
Rivaroxaban was FDA-approved in 2019 for venous thromboembolism (VTE) prophylaxis in acutely ill hospitalized patients. Little to no published data is available to determine the level of correlation between rivaroxaban drug concentration and UFH/LMWH ...
Kaitlin Blotske PharmD, Toral Patel PharmD, BCPS, Toby Trujillo PharmD, FCCP, FAHA, BCPS, Matthew Marlar MLS (ASCP), Stuart Lind MD, Henry Kramer MD, Kathryn Hassell MD, Tyree H. Kiser PharmD, FCCM, FCCP, BCCCP, BCPS   +7 more
doaj   +1 more source

Measurement of Active Thrombin Bound to Circulating D‐Dimers as a Sensitive Biomarker for Prothrombotic Conditions

Journal of Clinical Laboratory Analysis, EarlyView.
Scheme of preparation of D‐dimers and evaluation of D‐dimer‐bound thrombin activity. Thrombin bound to fibrin participates in ongoing fibrinogen transformation and its inhibition is impeded. Our detection system may aid in identifying patients at risk of recurrent thrombotic events or complications, regardless of the origin of the acute health problem.
Jana Stikarova, Leona Chrastinova, Kristyna Svobodova, Marek Havlicek, Jan Louzil, Eliska Ceznerova, Alzbeta Hlavackova, Ondrej Pastva, Pavla Pecherkova, Ingrid Hrachovinova, Ondrej Kucerka, Roman Kotlin, Petr Soukup, Peter Salaj, Martin Maly, Jiri Suttnar   +15 more
wiley   +1 more source

Patient-Reported Satisfaction and Study Drug Discontinuation: Post-Hoc Analysis of Findings from ROCKET AF. [PDF]

, 2019
IntroductionPatient-reported outcomes (PROs) and satisfaction endpoints are increasingly important in clinical trials and may be associated with treatment adherence.
Becker, Richard C, Berkowitz, Scott D, Breithardt, Guenter, Fox, Keith AA, Hacke, Werner, Halperin, Jonathan L, Hankey, Graeme J, Hellkamp, Anne S, Mahaffey, Kenneth W, Nessel, Christopher C, Patel, Manesh R, Piccini, Jonathan P, Rodriguez, Fatima, Singer, Daniel E, Ungar, Leo   +14 more
core   +1 more source

Extended thromboprophylaxis with betrixaban in acutely ill medical patients [PDF]

, 2016
BACKGROUND: Patients with acute medical illnesses are at prolonged risk for venous thrombosis. However, the appropriate duration of thromboprophylaxis remains unknown.
. Lodigiani, M, : W. Ageno, I, Cerveri, A., Cohen, Alexander T, De Pellegrin, D, D’Angelo, A, Gibson, C. Michael, Gold, Alex, Goldhaber, Samuel Z., Harrington, Robert A., Hernandez, Adrian F., Hull, Russell D., Imberti, R., Investigators, Italy (261 patients, 19 sites, Landolfi, G, LEMBO, Giuseppe, Luisetti, M., Wiens, Brian L.   +18 more
core   +1 more source

Incidence, contributing factors, and predictors of diagnostic errors in medical inpatients: A retrospective cohort study

Journal of Hospital Medicine, EarlyView.
Abstract Background Diagnostic error is a major patient safety concern in hospitals, yet most studies have focused on selected high‐risk subgroups, leaving the broader general internal medicine inpatient population understudied. Objectives To determine the incidence, contributing factors, resulting harm, and predictors of diagnostic error in medical ...
Caterina E. Marx, Elena Hofmann, Martin Perrig, Gurpreet Dhaliwal, Wolf Hautz, Jörg P. Isenegger, Ernst Lipp, Drahomir Aujesky, Manuel R. Blum, Tobias Tritschler   +9 more
wiley   +1 more source

Cost-effectiveness and budget impact analysis of rivaroxaban with or without aspirin compared to aspirin alone in patients with coronary and peripheral artery diseases in Iran

BMC Health Services Research
Background Low-dose aspirin and rivaroxaban are the cornerstone treatment for cardiovascular prevention in patients with peripheral artery disease (PAD) and/or stable coronary artery disease (SCAD).
Zahra Goudarzi, Zhila Najafpour, Ahmad Gholami, Khosro Keshavarz, Mohammad Mahdi Mojahedian, Mohammad Mehdi Babayi   +5 more
doaj   +1 more source

Dabigatran Concentrations in an Actively Breastfeeding Mother–Infant Dyad: Extending the Evidence for Oral Thromboprophylaxis Postpartum

American Journal of Hematology, EarlyView.
Rasmus W. Green, Aljona Saleh, Pawel Baranczewski   +2 more
wiley   +1 more source

Tranexamic Acid in Lower Extremity Endoprosthetic Reconstruction for Oncologic Indications: A Retrospective Comparative Study of 617 Patients

Journal of Surgical Oncology, EarlyView.
ABSTRACT Background and Objectives While tranexamic acid (TXA) reduces blood loss in orthopedic surgery, thromboembolic concerns in cancer patients have limited adoption in orthopedic oncology. This study evaluated TXA efficacy and safety in patients undergoing endoprosthetic reconstruction for oncologic indications.
Stephen W. Chenard, Akhil Rekulapelli, Riley S. Gilbertson, Connor S. Charton, William F. Hefley, Michael J. Colello, Jennifer L. Halpern, Herbert S. Schwartz, Daniel J. Johnson, Jonathan G. Schoenecker, Joshua M. Lawrenz   +10 more
wiley   +1 more source

Development of a physiologically‐based pharmacokinetic model for Ritonavir characterizing exposure and drug interaction potential at both acute and steady‐state conditions

CPT: Pharmacometrics &Systems Pharmacology, Volume 14, Issue 3, Page 523-539, March 2025.
Abstract Ritonavir (RTV) is a potent CYP3A inhibitor that is widely used as a pharmacokinetic (PK) enhancer to increase exposure to select protease inhibitors. However, as a strong and complex perpetrator of CYP3A interactions, RTV can also enhance the exposure of other co‐administered CYP3A substrates, potentially causing toxicity.
Lien Thi Ngo, Woojin Jung, Tham Thi Bui, Hwi‐yeol Yun, Jung‐woo Chae, Jeremiah D. Momper   +5 more
wiley   +1 more source